Anti-diabetic drug promises therapeutic solution to COVID-19 infection

An anti-diabetic drug ‘Ertugliflozin’, might provide a therapeutic solution to the COVID-19 infection as a repurposed drug. This is following ‘in-vitro’ and ‘in-silico’ studies done by the ASPIRE-BioN

An anti-diabetic drug ‘Ertugliflozin’, might provide a therapeutic solution to the COVID-19 infection as a repurposed drug. This is following ‘in-vitro’ and ‘in-silico’ studies done by the , a life sciences incubator jointly funded by Department of Biotechnology and University of Hyderabad (UoH), ReaGene Innovations and INDRAS private limited. The findings announced here on Thursday indicate that this repurposed drug not only binds effectively to the receptor binding domain of the spike protein of COVID-19 further blocks binding to human ACE2 but also displays significant anti-inflammatory and antithrombotic properties in a 3D human vascular lung model, both of which are fundamentals in COVID-19 infection, said an official press release.